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bjectives The aim of this study was to assess the inﬂuence of amount and distribution of calciﬁ-
ations of the aortic valve and the left ventricular outﬂow tract on the acute procedural outcome of
atients undergoing transcatheter aortic valve implantation (TAVI).
ackground Transcatheter aortic valve implantation is a new percutaneous technique especially for
lderly, high-risk patients with signiﬁcant aortic valve stenosis (AS). After TAVI, post-interventional
aravalvular aortic regurgitations (PAR) can occur, which is believed to be related partially to valve
alciﬁcations.
ethods We prospectively analyzed 100 symptomatic patients with severe AS scheduled for TAVI
ith the CoreValve ReValving (Medtronic, Minneapolis, Minnesota) prosthesis. In all patients, a native
nd contrast-enhanced multislice cardiac computed tomography was performed pre-interventionally.
alciﬁcation load of the valve and the adjacent outﬂow tract was estimated by the Agatston Score
AgS), and the amount and distribution of calciﬁcation was semi-quantitatively assessed and graded
n a 1 to 4 scale (device “landing zone” calciﬁcation score [DLZ-CS]). Aortography was performed to
valuate the PAR pre-interventionally, after initial device release (PAR0) and after termination of the
rocedure (PAR1). Transthoracic echocardiography was performed 2 weeks after implantation
PAR2).
esults The AgS and DLZ-CS showed a signiﬁcant correlation with the grade of PAR0 (AgS: r 
.329, p  0.001; DLZ-CS: r  0.356, p  0.001), PAR1 (AgS: r  0.254, p  0.011; DLZ-CS: r 
.240, p  0.016), and PAR2 (AgS: r  0.341, p  0.001; DLZ-CS: r  0.300, p  0.002). Both scores
AgS and DLZ-CS) showed a signiﬁcant positive correlation (r  0.858, p  0.001).
onclusions Calciﬁcation in the CoreValve device “landing zone” shows a signiﬁcant positive corre-
ation to PAR after TAVI. Furthermore, the need for “second maneuvers” (i.e., post-dilation after ini-
ial device release) can be predicted by these calciﬁcation scores (AgS and DLZ-CS). (J Am Coll
ardiol Intv 2010;3:233–43) © 2010 by the American College of Cardiology Foundation
rom the HELIOS Heart Center Siegburg, Department of Cardiology/Angiology, Siegburg, Germany. Study devices have been
rovided by CoreValve. Drs. Gerckens and Grube are proctors for Medtronic/CoreValve. The first 2 authors contributed equally
o this work.anuscript received August 26, 2009; revised manuscript received November 2, 2009, accepted November 5, 2009.
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234ercutaneous transcatheter aortic valve implantation (TAVI)
as introduced in 2002 (1) for treatment of severe symptom-
tic aortic valve stenosis (AS) in patients not eligible for
urgical valve replacement. Today, TAVI is a rapidly evolving
eld with almost exponentially increasing numbers of treated
atients as well as centers performing this intervention. Data
vailable so far demonstrate feasibility, safety, and efficacy of
his young technology in patients considered high-risk for
onventional surgical valve replacement (1–8), although these
esults are based on nonrandomized registry data and need to
e validated in randomized studies.
By now, 2 devices for TAVI
have been CE-marked—the
balloon-expandable Edwards-
Sapien prosthesis (Edwards Life-
sciences, Inc., Irvine, California)
and the self-expandable CoreValve
ReValving System (Medtronic,
Minneapolis, Minnesota).
A clinically relevant potential side
effect of TAVI is the development
of aortic regurgitation (AR) after
valve implantation. A mild-to-
moderate, post-interventionalAR is
present in approximately 50% of
patients (6). Previously published
data from our group demon-
strated a “33% rule”: probability of
unchanged, improved, and wors-
ened grades of AR is approxi-
mately 33% each (8). In 5% to
10% of cases, severe AR occurs
immediately after device release,
which can lead to serious and
life-threatening problems (2,3,6)
and which requires additional
“maneuvers” to be corrected. If
AR after TAVI occurs, it is
mainly localized in the paraval-
vular area (6).
Despite the clinical relevance
and its frequency, there are only
limited data available on this
mportant potential problem. However, recent observations
ndicate that the degree of post-interventional paravalvular
ortic regurgitation (PAR) depends on aortic valve cal-
ifications (AVC), which prevents a sufficient apposition
f the prosthesis to the native annulus (7).
Early developed calcification scores from the pre-TAVI
ra confirmed the aortic valve as the interesting area in
urgical valve replacement (9,10) and were recently trans-
erred to the collective of high-risk patients designed for
AVI (11,12) without consideration of the lower part of the
bbreviations
nd Acronyms
gS  Agatston score
R  aortic regurgitation
S  aortic valve stenosis
VC  aortic valve
alcification
T  computed tomography
LZ  device landing zone
LZ-CS  device landing
one calcification score
VOT  left ventricular
utflow tract
SCT  multislice
omputed tomography
AR  paravalvular aortic
egurgitation
AR0  angiographic aortic
egurgitation assessment
mmediately after device
eployment
AR1  angiographic aortic
egurgitation assessment at
he end of the procedure
AR2  transthoracic
chocardiography evaluation
f the regurgitation grade 2
eeks after the procedure
AVI  transcatheter aortic
alve implantationoreValve device landing zone (DLZ) (i.e., the left ven-ricular outflow tract [LVOT]). Therefore, we turned our
ttention on the aortic valve and the LVOT, which both are
art of the CoreValve DLZ.
The aim of this study was to assess the influence of
alcifications of the device “landing zone” on the procedural
uccess of the CoreValve prosthesis in patients with hemody-
amically significant AS. Furthermore, a semi-quantitative
i.e., visual 4-step) calcification score describing calcifications in
he DLZ was established and implemented to predict the
otential interventional outcome (i.e., incidence of significant
aravalvular leakage and need for post-dilation).
ethods
tudy design. A prospective single-center nonrandomized
tudy was performed to assess the influence of the total amount
nd distribution of calcification in the DLZ on the short-term
evice outcome with regard to PAR in patients undergoing
AVI with the third generation of the CoreValve prosthesis.
able 1 provides an overview on the examination steps. All
atients underwent computed tomography (CT) screening
efore the procedure as described in the following text. The
R during the procedure were assessed by repeated supra-
ortic angiograms immediately after device deployment
PAR0) as well as at the end of the procedure (PAR1) on the
asis of the established angiographic 0 to 4 scale according to
aim and Grossman (13).
Two weeks after the procedure, transthoracic echocardi-
graphy was performed to assess short time outcome of the
emodynamic valve status with particular evaluation of the
egurgitation grade (PAR2). The procedural result concern-
ng PAR (PAR0, PAR1, and PAR2) was analyzed by the
perators, who were blinded to the CT data concerning the
mount and distribution of calcification in the DLZ.
Clinical follow-up included 30 days after the procedure.
ll patients signed an informed written consent. This study
as approved by the local medical ethics committee.
atient population. We included 100 symptomatic high-
isk patients (age 82.10  6.25 years; 43 men) with severe
Table 1. Study Examinations and Timing
Timing Modality Comment
Pre-procedure CT scan Analyze calciﬁcations
Peri-procedure
After device deployment Aortogram Detect aortic regurgitation
(PAR0)
At the end of the procedure Aortogram Detect aortic regurgitation
(PAR1)
Post-procedure Echocardiography Detect aortic regurgitation
(PAR2)
CT computed tomography; PAR0 angiographic aortic regurgitation assessment immediately
after device deployment; PAR1 angiographic aortic regurgitation assessment at the end of the
procedure; PAR2  transthoracic echocardiography evaluation of the regurgitation grade 2weeks after the procedure.
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235S (aortic valve area: 0.61  0.17 cm2; mean transvalvular
ortic pressure gradient: 41.4  14.6 mm Hg). Additional
R was present at baseline in 79 cases (79%) (Table 2).
atient characteristics and comorbidities are presented in
ables 2 and 3. A patient was considered high-risk for
onventional surgery when excessive morbidity and/or mor-
ality (logistic EuroSCORE 20%, Society of Thoracic
urgeons score 10%) was predicted. Mean logistic Euro-
core was 24.8  18.8%, and mean Society of Thoracic
urgeons score was 21.6  9.9%.
aseline cardiac CT evaluation. In all patients, a native and
ontrast-enhanced multislice computed tomography
Table 2. Study Patient Characteristics (n  100)
Age, yrs 82 6.25
Male sex 57 (57)
EuroScore, % 24.8 18.8
STS score, % 21.6 9.9
Coronary artery disease 58 (58)
Prior percutaneous cardiac intervention
Prior percutaneous coronary intervention 35 (35)
Prior valvuloplasty of the aortic valve 4 (4)
Prior mitral valve replacement/repair 1 (1)
Prior bypass graft surgery 23 (23)
Left ventricular EF 48
Severe left ventricular dysfunction (EF 30%) 20
Aortic valve disease
Isolated aortic valve stenosis 21 (21)
Combined aortic valve disease with leading stenosis
and concomitant AR
79 (79)
AR 2 (pre-interventional) 23 (23)
Values are mean SD, n (%), or %.
AR aortic regurgitation; EF ejection fraction; STS Society of Thoracic Surgeons.
Table 3. Pre-Procedural Aortic Valve Characteristics
AVA, cm2*† 0.61 0.17
Mean pressure gradient, mm Hg* 41 15
Peak pressure gradient, mm Hg* 70 22
Peak-to-peak aortic gradient, mm Hg‡ 55 22
Aortic valve regurgitation‡ 1.1 0.7
Agatston score, AU§ 3,355 1,773
(range 790–11,007)
DLZ-CS 2.25 0.09
Most calciﬁed cusp, %§
Symmetric calciﬁcation without cusp accentuation 41
Noncoronary cusp 47
Left-coronary cusp 7
Right-coronary cusp 5
Annulus diameter, mm§ 24.14 1.96
Porcelain aorta, %§ 8
Data are expressed asmean SD. *Derived by transthoracic echocardiography. †For aortic valve
area (AVA) thecontinuityequationwasmostlyused; theaccuratedeterminationvia trans-esophageal
echocardiography was not feasible in one-third of the patients (36%) because of extensive valve
calcification. ‡Derived hemodynamically. §Derived by cardiac computed tomography.wDLZ-CS device landing zone calcification score.MSCT) (Philips Mx8000 IDT [Philips Medical Systems,
est, the Netherlands]; 16  0.75 mm; 120 kV; 160 mAs)
as performed before the procedure. The analysis of the
ative and contrast-enhanced images was separately accom-
lished with a commercially available computer workstation
Philips Extended Brilliance Workstation, Philips Medical
ystems) by 2 experienced investigators (S.Y., D.J.). Both
nvestigators were blinded to clinical data.
The native MSCT was performed for the quantitative
ssessment of the amount of calcification in the DLZ with
he Agatston score (AgS) as described elsewhere (14). The
rea of calcification in the DLZ was defined as at least 4
djacent pixels with a density of 130 Hounsfield Units
easured by native electrocardiography-gated cardiac
SCT. The DLZ was defined as the area including the
ortic valve (i.e., the aortic annulus and valvular cusps) and
he LVOT (until the junction point of the anterior mitral
eaflet). The measurement of the amount of calcification via
gS was performed in transverse source images in a stan-
ardized way and was averaged for statistical analysis.
The minimum requirements for the cardiac-CT CoreValve
creening process (i.e., the technical data for a sufficient data
cquisition for the contrast-enhanced MSCT) are shown in
able 4.
For the semiquantitative (i.e., visual) estimation of the
mount and distribution of calcification in the DLZ,
ontrast-enhanced cardiac CT images were used. Thus, for
valuation of calcification in the DLZ in a 3-dimensional
Table 4. MSCT CoreValve Screening Protocol Siegburg
ECG tagging No
Collimation 16  1.5 mm
Slice increment 1.0 mm
Rotation time 0.5 s
Pitch 1.2
Tube voltage 120 kV
Planned mAs 160 mAs/slice
SP ﬁlter Yes
Table speed 28.8 mm/s
Scan time 20–30 s
Image matrix 512  512
Contrast medium Imeron 400
Contrast volume 100–120 ml monophasic contrast (1.3 ml/kg body weight)
Injection speed 4 cc/s
Bolus-tracking Yes
NaCl-volume 50 ml (irrigation)
Delay BolusPro (variable)
Tracker To put in the descending aorta in the amount of the
diaphragm
Minimum requirements: data acquisition for angiography (16-slice multislice computed tomog-
raphy [MSCT]). The MSCT scan planning from above the aortic arch (including the left subclavian
artery as a possible access path) until the level of the middle third of the superficial femoral
arteries.
ECG electrocardiography; NaCl sodium chloride.ay, multiplanar reformations of the heart (including the
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236VOT and the aortic valve) and the ascending aorta were
sed. For this, 2 projections (i.e., coronal and single oblique
agittal view) were orthogonal orientated. The correct ori-
ntation was then confirmed by inspection of the so-called
ouble oblique transverse projection (Fig. 1). With this
rojection, we assessed amount of calcification on the level
f the aortic valve, cusp accentuation, calcification-caused
ommissural fusion (all via transversal view) and calcifica-
ion clumps outreaching the annulus level toward the
VOT, the latter via coronal single oblique sagittal view
Fig. 1). Atherosclerosis of the upper aortic root (distal to
he annulus level) of the proximal coronary arteries and the
itral annulus were excluded from the semi-quantitative
ssessment of calcification.
The total amount of calcification in the DLZ was assessed
emi-quantitatively and rated on the basis of the following
o-called DLZ calcification score (DLZ-CS): grade 1  mild
alcification, 2  moderate calcification, 3  heavy calcifica-
ion (mostly associated with commissural fusion), and 4 
assive calcification including big calcification clumps out-
eaching the annulus level. Examples of each grade are dis-
layed in Figure 2. In addition to this scoring system, the
Figure 1. Multiplanar Reconstruction for Evaluation of DLZ Calcification
Example of multiplanar reconstruction (coronal [top left], single oblique sagittal [t
evaluation of calciﬁcation in the CoreValve (Medtronic, Minneapolis, Minnesota) “la
outreaching the annulus level in caudal direction (device landing zone [DLZ] calciﬁcationistribution of aortic cusp calcification was assessed as sym-
etrical versus asymmetrical distribution. In case of asymmet-
ical distribution, the most calcified cusp was identified and fed
nto the analysis to detect calcification patterns in the overall
tudy population.
The quantitative amount of calcification in the DLZ was
lso rated on a 1 to 4 scale on the basis of the AgS (grade
: AgS1,000 AU; grade 2: AgS 1,001 to 3,000 AU; grade
: AgS 3,001 to 5,000 AU; grade 4: AgS 5,000 AU) and
ompared with the DLZ-CS.
oreValve device description and procedure. The current
hird-generation 18-F CoreValve aortic valve prosthesis
onsists of a trileaflet bioprosthetic valve made of porcine
ericardial tissue, which is mounted and sutured in a
elf-expanding nitinol frame. The prosthetic frame is
anufactured by laser-cutting of a nitinol metal tube
ith a total length of 50 mm. The upper portion of this
rosthesis is flared to anchor the stent in the ascending aorta
nd coaxial alignment. The middle portion is constrained to
void direct coverage of the coronary arteries. The lower part
arries the tissue valve and expands with high radial force
ithin the native valve annulus.
ht], and double oblique transversal view [bottom left]) for semi-quantitative
zone.” In this case calciﬁcation was visually determined as massive with clumpsop rig
ndingscore, grade 4).
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237The CoreValve procedure has been described previously
8) (Table 5). The device was implanted via retrograde
ransvascular approach (femoral or subclavian access) in all
atients.
pplied strategies in case of post-deployment regurgitation. In-
asive aortography was performed and analyzed by the
perators to evaluate pre-procedural AR, PAR after initial
elease (PAR0), and acute post-procedural AR (PAR1) and
as used as the basis for the decision for further strategies.
nterventional options in case of more-than-moderate post-
eployment regurgitation (PAR0 grade 2) included
ost-dilation, device repositioning with a snare catheter
nd/or implantation of a 2nd CoreValve prosthesis (valve-
n-valve replacement/2 valves “in series”). Application of
hese escalating measures was at the operator’s discretion.
eﬁnitions. Device success was defined as stable device
lacement and adequate function in the first attempt as
ssessed by angiography. Acute procedural success was
efined as device success with absence of periprocedural
ajor adverse cardiovascular and cerebral events including
ardiac tamponade in the first 24 h after device implanta-
Figure 2. The DLZ Calcification Score Provides 4 Grades of Calcification
The device landing zone calciﬁcation score (DLZ-CS) provides 4 grades of calci
(B) DLZ-CS, grade 2  moderate calciﬁcation; (C) DLZ-CS, grade 3  heavy ca
noncoronary and left coronary cusp]); (D) DLZ-CS, grade 4  massive calciﬁcation. Major adverse cardiovascular and cerebral events con- sisted of death from any cause, myocardial infarction (cre-
tine kinase-myocardial band more than 2 times the upper
imit of normal), and stroke (as assessed by routine neuro-
ogical assessment before and after procedure and before
ospital discharge). Clinical adverse events were adjudicated
y an independent clinical events committee.
ata analysis. All data were analyzed with the SPSS statis-
ical utility software (SPSS, Inc., Chicago, Illinois). Cate-
orical variables are presented as frequencies; continuous
ariables are presented as mean  SD. Differences were
ssessed with a paired-sample t test for normally distributed
ata. For correlations, Pearson bivariate analysis with a
-tailed test for significance was used. A p value  0.05 was
onsidered significant.
esults
linical outcome. The procedural data are shown in Table 6. In
7 of 100 patients a trans-femoral approach was used
ithout general anesthesia. Device implantation was suc-
essful in 99 patients. One patient died on day 1 during
n in the device “landing zone”: (A) DLZ-CS, grade 1  mild calciﬁcation;
ion (mostly associated with commissural fusion [in this case between the
cluding big calciﬁcation clumps outreaching the annulus level).ﬁcatio
lciﬁcaturgical pericardiocentesis for treatment of periprocedural
Table 5. Morphologic Selection Criteria for CoreValve TAVI
Noninvasive Angiography Selection Criteria
Anatomy Echo CT/MRI LV, g AO, g Coronary Angiogram
AO and
Runoffs Preferred Borderline Not Acceptable
Atrial or ventricular thrombus X Not present Present
Mitral regurgitation X Grade 1 Grade 2 Grade 2
LV ejection fraction X X 50% 30%–50% 20%
LV hypertrophy (wall thickness) X Normal to mild (0.6–1.3 cm) Moderate (1.4–1.6 cm) Severe (1.7 cm)
Subaortic stenosis X X Not present Present
Annulus (width) X X 20–3 mm–26 mm device
24–27 mm–29 mm device
20 or 27 mm
Annulus-to-AO (angle degrees) X X X 30 30–45 45
AO root (width) X X X 30 mm 27–29 mm 27 mm (if sinus 15 mm)
Sinuses of valsalva (height) X X X X  15 mm 10–14 mm 10 mm
Coronary ostia position (take-off) X High Mid-sinus level Low
Coronary disease X None, mild, or distal stenosis 70% Proximal stenosis 70%
Ascend AO (width) X X X 40 mm–26 mm device
43 mm–29 mm device
43 mm
AO arch angulation X X X Large-radius turn High angulation or sharp bend
Aorta and run-off vessels
(disease)
X X None Mild Moderate to severe
Iliac and femoral vessels
(diameter)
X X 7 mm nondiabetic
6 mm
6 mm
AO aorta; CT computed tomography; Echo echocardiography; LV left ventricular; MRImagnetic resonance imaging; TAVI transcathether aortic valve implantation.
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239ericardial tamponade caused by right ventricular perfora-
ion due to the temporary pacemaker wire. Periprocedural
ajor adverse cardiovascular and cerebral events rate was
%, including death (1%) and stroke (0%). The 30-day
ll-cause mortality rate was 7%.
rocedural hemodynamic valve performance. The hemody-
amic results are presented in Table 7. The TAVI
rocedure resulted in a decrease in mean pressure gradi-
nt from 41  15 mm Hg to 9  4 mm Hg and a
ecrease of the peak pressure gradient from 70  22 mm
g to 17  8 mm Hg.
Table 6. Procedural and 30-Day Outcome
Number of patients treated, n 100
“Small” (26-mm) CoreValve prosthesis 51
Combined procedures (CoreValve  PCI) 7
Access site
Femoral/iliacal artery 97
Subclavian artery 3
Device success, n (%) 99 (99)
Acute success 65 (65)
Second maneuver necessary* 34 (34)
Post-dilation after CoreValve implantation 34 (34)
Correction via snare catheter 4 (4)
Second prosthesis necessary (valve-in-valve replacement/
2 valves “in series”)
3 (3)
30-day all-cause mortality, n (%) 7 (7)
Cardiac mortality, n (%) 5 (5)
Myocardial infarction, n (%) 1 (1)
Stroke, n (%) 1 (1)
30-day MACCE 6 (6)
Valve dysfunction or valve migration 0
*Percentages are not additive; sometimes variousmaneuvers in the samepatientwerenecessary.
MACCE  major adverse cardiovascular and cerebral events; PCI  percutaneous coronary
intervention.
Table 7. Comparison of the Pre- and Post-Procedural Hemodynamic Valve P
Pre-Procedural Afte
Number of patients 100
Mean pressure gradient, mm Hg 41 15
Peak pressure gradient, mm Hg 70 22
AVA, cm2 0.61 0.17
Aortic valve regurgitation, ° 1.10 0.70¶ 1.3
4 0
3 2
2 21
1 56
0 21
Values are n ormean SD. *Assessed after initial release of the CoreValve prosthesis.†Values after p
patient diedduring theCoreValve implantation as a result of peri-procedural pericardial tamponade
For aortic valve area (AVA), the continuity equation was used. ¶Derived hemodynamically.
AR 0 pre-procedural aortic valve regurgitation; PAR0 angiographic aortic regurgitation assesend of the procedure; PAR2 transthoracic echocardiography evaluation of the regurgitation grade 2 weeThe AR increased from 1.1  0.7 before procedure (AR
) to 1.3  0.9 immediately after deployment of the
oreValve prosthesis (PAR0) in the overall population. In
4 patients (34%), additional maneuvers after device de-
loyment were necessary due to more-than-moderate ARs.
ll of these patients underwent post-dilation. In 4 of these
atients a repositioning maneuver with a snare catheter was
ttempted, due to an additional so-called “deep position,”
hich caused suboptimal results after post-dilation. This
nare maneuver improved the AR in 1 patient; the remain-
ng 3 patients underwent a second implantation of a
oreValve prosthesis (valve-in-valve replacement or 2 valves
in series”), which improved the regurgitation grade in all
ases (Table 6).
Final regurgitation grade after correction measures was 0.9 
.8 (PAR1) in the overall population. This result remained
onstant after a 2-week period, with a PAR of 0.9  0.6
PAR2), taking into consideration that acute PAR after ter-
ination of the procedure (PAR1) was determined by invasive
ortography whereas PAR2 was determined by transthoracic
chocardiography. None of these changes were statistically
ignificant (Table 7, Fig. 3). However, in patients with the
eed for post-dilation, grade of PAR was significantly decreased
rom PAR0 of 2.2  0.5 to PAR1 of 1.3  0.3 (p  0.001).
T data and correlation analysis. The data derived from
ardiac CT are shown in Table 3. The amount of calcifi-
ation, measured semiquantitatively by the (DLZ-CS) was
.25  0.09. The amount of calcification, measured quan-
itatively by the AgS was 3,355  1,773 AU, ranging from
90 to 11,007 AU. Both, AgS and DLZ-CS correlated
ignificantly in a positive fashion (r  0.858, p  0.001)
Fig. 4). The DLZ-CS grade 1 (mild calcification) equates
o an AgS of 1,000 AU, DLZ-CS grade 2 (moderate
alcification) equates to an AgS of 1,001 to 3,000 AU,
LZ-CS grade 3 (heavy calcification) equates to an AgS
mance
ase* Acute Post-Procedural† At 2-Week Follow-Up
99‡ 94§
9 4
17 8
1.43 0.31
10¶ 0.90 0.10¶ 0.90 0.10
0 0
1 0
11 10
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tion, necessary in 34 cases, and position adjustment (via snare catheter), necessary in 4 cases.‡One
atients diedduring the 2-week follow-up. Derivedby standard transthoracic echocardiography.
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240,001 to 5,000 AU, and DLZ-CS grade 4 (massive calcifi-
ation with calcification clumps outreaching the annulus
evel) equates to an AgS 5,000 AU (Table 8).
In 47% of the aortic valves the noncoronary cusp was—
egarding the distribution of AVC—the most calcified,
ollowed by the left-coronary (7%) and right-coronary cusp
5%). Forty-one percent showed a symmetric valve calcifi-
ation without cusp accentuation.
The amount of calcification in the DLZ, measured by the
onventional AgS, showed a weak although statistically
ignificant positive correlation with the grade of PAR0 (r 
Figure 3. Degree of Pre-, Peri-, and Post-Procedural AR
Degree of aortic valve regurgitation (AR) pre-procedural (AR 0), immedi-
ately after CoreValve release (PAR0), after termination of the procedure
(PAR1), and 2 weeks afterward (PAR2). No signiﬁcant differences between
the AR at the 4 time points are observed in all patients (p  0.05).
Figure 4. Relationship Between AgS and DLZ-CS
Relationship between the Agatston score (AgS) and the device landing zone c
tion (r  0.858, p  0.001)..329, p  0.001) (Fig. 5), PAR1 (r  0.254, p  0.011)
Fig. 6), and PAR2 (r  0.341, p  0.001). The amount of
alcification in the DLZ, visually assessed by the DLZ-CS,
lso showed a weak statistically significant positive correla-
ion with the grade of PAR0 (r  0.356, p  0.001), PAR1
r  0.240, p  0.016), and PAR2 (r  0.300, p  0.002).
Furthermore, these 2 scoring systems (AgS and DLZ-
S) showed a weak but significant correlation with the need
or post-dilation of the CoreValve prosthesis after initial
evice release (r  0.297, p  0.003 for AgS; r  0.300,
 0.002 for DLZ-CS).
However, at least in our population, there was no out-
ome correlation with the distribution pattern of valve
alcifications (Fig. 7).
iscussion
ranscatheter aortic valve implantation is an established
rocedure in elderly, high-risk patients with significant
S (1–8).
tion score (DLZ-CS). The AgS and DLZ-CS show a signiﬁcant positive correla-
Table 8. Classification of Calcification Types
DLZ-CS
Grade Comment AgS (AU)
1 Mild calciﬁcation 1,000
2 Moderate calciﬁcation 1,001–3,000
3 Heavy calciﬁcation (mostly with commissural fusion) 3,001–5,000
4 Massive calciﬁcation (with calciﬁcation clumps
outreaching the annulus level)
5,000
AgS Agatston score; DLZ-CS device landing zone calcification score.alciﬁca
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241Data currently available for TAVI suggest that this
ethod is feasible and provides hemodynamic and, more
mportantly, clinical improvement for up to 2 years in
igh-risk patients suffering from severe AS (6).
Development of post-procedural PAR is one of the
otential problems associated with TAVI. In theory, in-
omplete expansion of the CoreValve nitinol frame, mis-
atch of valve annulus and prosthesis diameter sizes, or
uboptimal device positioning—too low or too high com-
ared with the annulus level—can result in AR after device
Figure 5. Relationship Between AgS and PAR After Device Release
Relationship between Agatston score (AgS) pre-implantation and the aortic reg
sota) (PAR0) is shown (r  0.329, p  0.001). The regression equation calculat
Figure 6. Relationship Between AgS and Post-Procedural PAR
Relationship between Agatston score (AgS) pre-implantation and the aortic reg
0.011).eployment. Previous studies have shown that the incidence
f a more-than-moderate PAR after CoreValve implanta-
ion is approximately 5% to 10% (2,3,6). Approximately
ne-third of patients undergoing TAVI experience a wors-
ning of their pre-procedural grade of AR (8). Incomplete
evice expansion due to calcifications is believed to be one of
he major contributing factors, but up to now, there have
een no scientific data available supporting this theory.
We therefore conducted this study, comparing calcifica-
ions in the DLZ assessed by MSCT and post-procedural
tion immediately after CoreValve release (Medtronic, Minneapolis, Minne-
AR0  0.677  0.000181 AgS.
tion immediately after CoreValve procedure (PAR1) is shown (r  0.254, p urgitaurgita
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242ncidence of paravalvular leakages. The ability to quantify
alve calcification by cardiac MSCT has been shown previ-
usly and has been validated by histomorphometric and
athological analysis (15–19). The AgS (14) is known as a
alid measure of objective noninvasive definition of in vivo
alcification. Even more, an increased progression rate of
S has been observed in patients with aggravated AVC
20), and the degree of AVC is an independent predictor for
dverse clinical outcomes (9,21,22). The pre-surgical
nowledge of the extent of AVC is of importance to the
ardiac surgeon, because the surgical aortic valve replace-
ent outcome is influenced by this parameter (23–27).
Therefore, MSCT in patients with AS already plays an
mportant role. Early developed calcification scores from the
re-TAVI era focused on the aortic valve as the interesting
rea in surgical valve replacement in patients with AS
9,10). Furthermore, the semiquantitative AVC 4-step scor-
ng system developed by Rosenhek et al. (9) contains grades
ith a lack of calcification (i.e., “grade 1” [no calcification]).
ore recently available studies, however, suggest that, in
atients with hemodynamically increased transvalvular aor-
ic gradients due to aortic valve stenosis, AVC is constantly
resent (15,16), which was affirmed by Willmann et al.
10)—who found no patients with “grade 1” AVC with this
arly calcification score in patients with severe AS. These
ndings are in line with our data. The semiquantitative
VC score developed by Rosenhek et al. (10) has been
Figure 7. Degree of PAR0 According to Aortic Valve Cusp
Calcium Localization
Degree of aortic valve regurgitation assessed by angiography acute after
release of the CoreValve prosthesis (PAR0) according to calcium localization
of the aortic valve cusps. The middle line of each bar represents the
median. The horizontal line extends from the minimum to the maximum
value, excluding “outside” and “far out” values. An outside value is deﬁned
as a value that is smaller than the lower quartile minus 1.5 times the inter-
quartile range or larger than the upper quartile plus 1.5 times the inter-
quartile range. 0  symmetrical distribution with no accentuation of
calciﬁcation; 1  noncoronary cusp; 2  right coronary cusp; 3  left coro-
nary cusp.ecently transferred to the collective of high-risk patients tesignated for TAVI (11,12) without consideration of the
ower part of the CoreValve DLZ (i.e., the LVOT). For the
ollective of patients undergoing TAVI we turned our
ttention to the aortic valve and the LVOT, which are both
art of the CoreValve DLZ because, in patients with severe
S, calcification is often not limited to the aortic valve level.
ur data demonstrate that the amount of calcification of the
ortic valve and the LVOT shows a significant positive
orrelation to PAR after TAVI. Therefore, calcification in
he DLZ impairs the short-term device outcome of the
oreValve prosthesis in patients with severe AS due to
ncomplete apposition of the TAVI prosthesis within the
ative annulus and the wall of the LVOT. After CoreValve
mplantation, the calcium of the native valve and the LVOT
s sandwiched between the nitinol frame of the prosthesis
nd the aortic wall, respectively. This factor induces gaps
hat in turn cause several diastolic paravalvular regurgitation
ets that add up to a noticeable regurgitation.
The cusp accentuation of these calcifications is more than
0% asymmetrical—as shown in our study. In nearly 50% of
ur collective, the noncoronary cusp was the most calcified
ne. In our patients, the distribution of calcification of the
ortic valve cusps did not influence the post-procedural
egree of PAR. Whether this will prove true in a larger
ohort of patients remains to be studied.
Balloon post-dilation in cases with more-than-moderate
AR is a safe and often practiced maneuver, as shown in our
tudy, taking place in approximately one-third of cases. In
one of the 34 cases in which this maneuver was performed
id a patient-related (myocardial infarction, stroke) or
evice-related (rupture, valve dysfunction, or migration)
omplication occur. With this technique, the post-
nterventional result concerning PAR can be remarkably
mproved as demonstrated.
To quantify and qualify calcifications in the DLZ in
atients undergoing TAVI, no adequate calcification scor-
ng system has been validated. We developed a semi-
uantitative 4-step calcification scoring system (DLZ-CS)
or symptomatic patients with hemodynamically significant
S that provides a semi-quantitative scale with consider-
tion of the calcification pattern. Both calcification scores
DLZ-CS and AgS) showed a significant positive correla-
ion in our analysis, demonstrating that these scores are
pplicable.
We found that a DLZ-CS 3 and/or an AgS 3,000
U predicts a relevant PAR (PAR2) after initial release
f the CoreValve prosthesis (PAR0) and, moreover, the
eed for “second maneuvers” (i.e., post-dilation after initial
elease of the CoreValve prosthesis).
Consecutively, before TAVI, a pre-interventional cardiac
T imaging including the determination of calcification in
he DLZ is recommended to specify the likely interven-
ional outcome.
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243For the estimation of the AgS, a native MSCT is
equested. The DLZ-CS has the advantage that the
ontrast-enhanced CT, which is performed before interven-
ion as part of the regular TAVI screening process, suffices
s assessment of the amount and distribution of calcification
n the DLZ.
tudy limitations. The evaluation of AR at the 4 time points
as performed with different methods. The pre-
nterventional AR (AR 0) and PAR after device release
PAR0) and after termination of the procedure (PAR1)
ere determined by invasive aortography, whereas the PAR
weeks afterward (PAR2) was determined by transthoracic
chocardiography. Therefore, the comparison of the acute
ost-procedural PAR (PAR1) and short-term PAR (PAR2)
s limited.
It must be taken into consideration that the cause of acute
ost-procedural AR can also be due to other correctable
actors: 1) the prosthesis size does not match the anatomical
eeds; this problem can be overcome by meticulous pre-
rocedural screening by contrast-enhanced cardiac MSCT
ith multiplanar reconstruction demonstrated in Figure 1;
nd 2) the prosthesis sits too deep in the LVOT, the
o-called “deep position”; careful pulling and re-positioning
y means of a snare catheter, either through the femoral or
he brachial approach, can correct this problem.
However, with an increasing amount of calcification, the
ccurrence of PAR and therefore the need for post-dilation
ncreases. Further parameters are required to predict the
rocedural outcome. Furthermore, experienced operators
re necessary to control possible complications during the
oreValve procedure.
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